Haima Therapeutics
Haima Therapeutics is a preclinical-stage biopharmaceutical company developing SynthoPlate, a fully synthetic IV-injectable platelet surrogate for hemorrhage control in trauma, surgery, thrombocytopenia, and military battlefield applications, advancing toward IND submission in 2027.
- Company typePrivate
- Founded2016
- HeadquartersCleveland, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Haima Therapeutics does
Haima Therapeutics, LLC is a preclinical-stage biopharmaceutical company founded in 2016 in Cleveland, Ohio, developing cell-inspired therapies for the treatment of bleeding and blood-related diseases. The company's lead product, SynthoPlate, is a fully synthetic, IV-injectable hemostatic nanoparticle that mimics and amplifies platelet adhesion (via CBP and VBP peptides) and aggregation (via GPIIb-IIIa-mimicking FMP peptide) functions. The technology uses proprietary peptide-decorated liposomes that can be stored as liquid or lyophilized powder, with 12+ months shelf stability and reconstitution in under one minute. The platform is exclusively licensed from Case Western Reserve University, where co-founder and CTO Anirban Sen Gupta invented the technology in the Department of Biomedical Engineering.
Haima's target indications span multiple high-burden clinical scenarios: pre-hospital trauma hemorrhage, complex surgical bleeding, thrombocytopenia (over 750,000 US patients annually receive donor platelet transfusions), traumatic brain injury in patients on antiplatelet therapy, von Willebrand disease, and military battlefield hemorrhage control. The company also operates a broader Platelet-Inspired Platform Technology extending into thrombosis, thromboinflammation, and cancer metastasis applications. Distribution upon regulatory approval will target trauma centers, hospitals, and healthcare systems via enterprise field sales, alongside military medical supply chains and veterinary clinics.
The company has been funded entirely through approximately $61M+ in non-dilutive SBIR grants and government contracts from NIH, NSF, DoD, and DARPA, including integration into the $46M DARPA FSHARP whole blood surrogate program. Haima is currently raising a Series A round to advance SynthoPlate toward IND submission planned for early 2027, with first-in-human clinical trials to follow. The company employs 1-10 people and is led by CEO Michael Bruckman, PhD, alongside CMO Dr. Matthew Neal, COO Christa Pawlowski, PhD, CTO Anirban Sen Gupta, PhD, and Executive Chair Timothy Pelura, PhD.
Haima Therapeutics firmographics
Firmographics- Name
- Haima Therapeutics
- Legal name
- Haima Therapeutics, LLC
- Website
- https://haimatherapeutics.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Haima Therapeutics is a preclinical-stage biopharmaceutical company developing SynthoPlate, a fully synthetic IV-injectable platelet surrogate for hemorrhage control in trauma, surgery, thrombocytopenia, and military battlefield applications, advancing toward IND submission in 2027.
- Ownership category
- akta.pro rank
Haima Therapeutics industry classification
Industry- Product category
- Hemostatic Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Blood Factors & Hemostasis Biologics (recombinant clotting factors, thrombolytics) (HLAAAAAL)
Keywords
Where Haima Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Cleveland
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Haima Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Product Sales: Revenue from commercial sale of SynthoPlate as an IV-injectable hemostatic drug for trauma, surgery, and thrombocytopenia indications. Company is preclinical stage; no commercial products yet.
- Licensing Royalties: Exclusive license agreement with Case Western Reserve University for synthetic platelet technology. May generate licensing revenue from the technology platform.
- Government Contracts and SBIR Grants: Non-dilutive funding from DARPA, DoD, NIH, and NSF SBIR awards supporting development. Multiple grants totaling over $10M to advance SynthoPlate toward clinical use.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Haima Therapeutics product offering
Product offeringCore offering
Haima Therapeutics is developing SynthoPlate, a fully-synthetic, IV-injectable hemostatic agent that mimics and amplifies platelet adhesion and aggregation functions to stop bleeding in patients with traumatic injury, surgery, thrombocytopenia, and rare bleeding disorders. The technology uses peptide-decorated liposomes (CBP, VBP, FMP) and can be stored as liquid or lyophilized powder for shelf-stable, field-deployable use.
Product overview
Haima Therapeutics is a pre-clinical stage biopharma company developing cell-inspired therapies for bleeding treatment and blood-related diseases. The company operates with two main offerings: (1) SynthoPlate, a fully-synthetic, nanoparticle-based hemostatic agent that serves as a platelet surrogate to mitigate bleeding by acting at injury sites and amplifying natural clotting mechanisms; and (2) a Platelet-Inspired Platform Technology that enables targeted drug delivery across multiple therapeutic applications. SynthoPlate is the company's lead product targeting traumatic injury, surgery, and thrombocytopenia indications. The technology was licensed from Case Western Reserve University and is advancing toward IND submission in early 2027 with support from DARPA and NIH funding.
Differentiator
Problem solved
Functional benefit
Brands
- SynthoPlate: A platelet-inspired, IV-injectable fully-synthetic hemostatic agent that mimics and amplifies platelet adhesion and aggregation functions to stop bleeding in patients with low platelet counts or platelet dysfunction.
Products and services
- SynthoPlate SynthoPlate is a fully-synthetic, IV-injectable hemostatic agent that mimics and amplifies platelet adhesion and aggregation functions to stop bleeding in patients with low platelet counts or platelet dysfunction. It targets traumatic injury, surgery, and thrombocytopenia indications and can be stored as liquid or lyophilized powder for shelf-stable, field-deployable use.
Quantifiable outcome
- Reduced blood loss by ~56% in rat liver laceration model with lyophilized SynthoPlate via intraosseous injection
- +4 more outcomes
Companies that use Haima Therapeutics
Customer profileSegments6 records
Ideal customer profiles3 records
Haima Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Haima Therapeutics partnerships and signals
Strategic signalPartnerships
14 partnerships are on record, tiered flagship, core and minor.
- DARPA (FSHARP Program)flagshipHaima is an integral part of DARPA's $46M FSHARP (Fieldable Solutions for Hemorrhage with bio-Artificial Resuscitation Products) program led by University of Maryland, Baltimore. Haima's role focuses on the hemorrhage control component by providing SynthoPlate as part of a whole blood surrogate alongside oxygen-carrying and plasma components.
- University of Maryland, BaltimorecoreLead institution for DARPA FSHARP program. Collaborating with Haima to develop a shelf-stable whole blood equivalent combining SynthoPlate with oxygen-carrying and plasma components.
- KaloCyte Inc.coreCollaboration on ErythroMer (red blood cell surrogate) co-administration with SynthoPlate. Evaluating fully dried whole blood surrogate (WBS) combining Haima's synthetic platelets with ErythroMer and lyophilized plasma for field-deployable resuscitation.
- University of PittsburghcoreMulti-year collaboration with Dr. Matthew Neal (Co-investigator) at Pittsburgh Trauma Research Center. Dr. Neal serves as CMO of Haima and collaborates on preclinical and clinical development of SynthoPlate. Also consortium partner in DARPA FSHARP program.
- Charles River LaboratoriesminorFSHARP consortium partner providing preclinical development services and expertise.
- Teleflex IncorporatedminorFSHARP consortium partner contributing to whole blood surrogate development.
- Latham Biopharm GroupminorFSHARP consortium partner in whole blood surrogate development.
- Ohio State UniversityminorFSHARP consortium partner contributing research expertise.
- Southwest Research InstituteminorFSHARP consortium partner providing research capabilities.
- University of California San DiegominorFSHARP consortium partner contributing academic research expertise.
- U.S. Army Institute of Surgical Research (USAISR)coreDoD MRDC awarded $1.4M cooperative agreement to evaluate co-administration of SynthoPlate with lyophilized plasma to create HELP (Hemostatically Enhanced Lyophilized Plasma) product in collaboration with Dr. Michael A. Meledeo at USAISR, San Antonio.
- University of Maryland - Baltimore (Doctors Allan Doctor and Dipanjan Pan)coreDoD CRRP $1.6M research contract to evaluate co-administration of SynthoPlate with ErythroMer and lyophilized plasma for fully dried whole blood surrogate (WBS) in collaboration with Drs. Allan Doctor and Dipanjan Pan.
- KaloCyte Inc. (ErythroMer Developer)coreKaloCyte developed ErythroMer, a novel red blood cell surrogate. Haima collaborating to evaluate co-administration of SynthoPlate with ErythroMer and lyophilized plasma for fully dried whole blood surrogate.
- Case Western Reserve UniversitycoreExclusive license agreement for SynthoPlate synthetic platelet technology developed by Professor Anirban Sen Gupta in CWRU's Department of Biomedical Engineering. Haima licensed the technology for research, development, and commercialization of hemostatic therapies.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Haima Therapeutics competitors and assessment
Company assessmentDirect peers
- Cresilon (formerly Cresilon Inc.): Commercializing Veti-Gel, a plant-based hemostatic gel for rapid bleeding control in trauma and surgical settings. Comparable as a synthetic/biomimetic hemostasis company targeting both human and veterinary hemorrhage with novel, non-donor-dependent mechanisms.
- KaloCyte Inc. Developer of ErythroMer, a freeze-dried red blood cell surrogate. Direct FSHARP consortium partner with Haima, co-developing a field-deployable whole blood surrogate. Highly comparable as a synthetic blood component company targeting trauma and military applications.
- Velico Medical: Developing spray-dried plasma technologies for transfusion medicine. Direct partner-adjacent peer in the dried/shelf-stable blood surrogate space and a fellow FSHARP-aligned collaborator targeting pre-hospital and battlefield resuscitation.
- Cellphire Therapeutics: Developing Thrombosomes, a lyophilized platelet product for hemostasis in surgery and trauma. Most directly comparable to Haima's SynthoPlate as a synthetic/lyophilized platelet surrogate targeting hemorrhage control, with overlapping clinical indications and similar biopreservation/formulation challenges.
- Arch Therapeutics: Developing AC5, a self-assembling peptide hemostatic agent. Comparable as an early-stage synthetic hemostatic technology targeting surgical and trauma bleeding with a novel non-blood-derived mechanism of action.
Broad incumbents
- CSL Behring: Global leader in blood plasma-derived and recombinant biologic therapies for hemophilia, von Willebrand disease, and thrombocytopenia. Comparable as a broad incumbent operating across Haima's primary indications and a likely strategic acquirer or commercialization partner for SynthoPlate.
- Grifols: Major plasma products and blood-component manufacturer with a broad hemostasis franchise. Comparable as a large incumbent whose plasma-derived and recombinant hemostatic products address overlapping indications and which could potentially distribute or partner SynthoPlate post-approval.
- Octapharma: Privately-held global manufacturer of human proteins and coagulation factor products, including therapies for von Willebrand disease. Comparable as a broad blood-product incumbent overlapping SynthoPlate's hematology indications and a candidate strategic partner.
- Takeda Pharmaceutical (Baxalta/Shire hematology franchise): Global pharmaceutical company with a large hematology franchise covering hemophilia, thrombocytopenia, and rare bleeding disorders. Comparable as a broad incumbent operating across many of Haima's target indications and a likely M&A or licensing partner for an approved synthetic platelet product.
Emerging players
- Coagulant Therapeutics: Developing synthetic coagulant factor therapies for bleeding disorders. Comparable as an emerging biotech pursuing synthetic alternatives to blood-derived coagulation products, though focused on factor replacement rather than platelet mimicry.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Haima Therapeutics social profiles
Digital presenceHaima Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Haima Therapeutics leadership team
Management profileNumber of profiles
Profiles10 records
Haima Therapeutics funding detail
Funding detailFunding overview
Funding rounds5 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Haima Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Haima Therapeutics
What does Haima Therapeutics do?
Haima Therapeutics is developing SynthoPlate, a fully-synthetic, IV-injectable hemostatic agent that mimics and amplifies platelet adhesion and aggregation functions to stop bleeding in patients with traumatic injury, surgery, thrombocytopenia, and rare bleeding disorders. The technology uses peptide-decorated liposomes (CBP, VBP, FMP) and can be stored as liquid or lyophilized powder for shelf-stable, field-deployable use.
Is Haima Therapeutics a public or private company?
Haima Therapeutics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Haima Therapeutics founded?
Haima Therapeutics was founded in 2016. It employs 1 to 10 people.
Where is Haima Therapeutics based?
Haima Therapeutics is headquartered in Cleveland, United States, in the North America region.
How does Haima Therapeutics make money?
Three revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing Royalties and government Contracts and SBIR Grants.
Who are Haima Therapeutics's main competitors?
Direct peers on record are Cresilon (formerly Cresilon Inc.), KaloCyte Inc., Velico Medical, Cellphire Therapeutics and Arch Therapeutics. Broad incumbents are CSL Behring, Grifols, Octapharma and Takeda Pharmaceutical (Baxalta/Shire hematology franchise). Coagulant Therapeutics is listed as an emerging player.
Does Haima Therapeutics have an API?
No public API is recorded for Haima Therapeutics.
What industry is Haima Therapeutics in?
Haima Therapeutics's product category is Hemostatic Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAL, Blood Factors & Hemostasis Biologics (recombinant clotting factors, thrombolytics). Its NAICS code is 325414 and its SIC code is 2836.